Africa Institutional Audit 1994, just published by the market research company IMS' affiliate Research Consultants International, provides comprehensive data on tender awards in Ethiopia, Ghana, Tanzania and Zimbabwe. The total value these awards was as follows:
Country Value Zimbabwe* $20.2 million Ethiopia $9.3 million Tanzania $3.9 million Ghana $0.8 million * including Zimbabwe's expanded program of immunization (ZEPI) 1993/94 vaccine purchases ($6.8 million).
The largest classes of products appearing in the awards were as follows: for Zimbabwe (Ministry of Health awards excluding ZEPI), rifampicin/rifamycin, antiparasitics and analgesics; for Ethiopia, penicillins, systemic corticosteroids and antiparasitics; for Tanzania, psycholeptics, macrolides and antiparasitics; and for Ghana, tuberculostatics, rifampicin/rifamycin and psycholeptics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze